Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Postoperative Triple Targeted Therapy in CHD-PAH
NCT07844213Completed
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of treprostinil in congenital heart disease (CHD) and pulmonary hypertension (PH) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Pulmonary vascular resistance at 12 months. Started Aug 2022; status: completed.
02
Drugs
treprostinil
03
Conditions
congenital heart disease (CHD)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07844213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844213.